CLINICAL CHARACTERISTICS, MEDICAL AND NUTRITIONAL MANAGEMENT OF NON-SEVERE HOME- QUARANTINED COVID-19 PATIENTS IN PAKISTAN: A RETROSPECTIVE STUDY

Main Article Content

Asra Iftakhar
Fahad Asim
Rabia Altaf
Rabia Haq
Kanwal Mazhar
Mazhar Javed
Maryam Iftikhar
Bushra Mazhar
Irum Fatima
Sana Saeed
Kanwal Asif
Muhammad Danyal Javed
Bilal Ahmed

Keywords

Home-quarantine, COVID-19, Oxygen saturation, antipyretics, immunity

Abstract

Background/Objectives: The majority of coronavirus-infected patients were reported to have mild symptoms and home treatment of these individuals was successful without considerable mortality. The purpose of the present study was to determine the epidemiological and clinical characteristics as well as treatment approaches, nutritional status, and outcomes of home quarantines of non-severe COVID-19 patients.


Methods: A total of 365 COVID-19 non-severe patients with stable medical conditions were enrolled in the study. Data regarding clinical features such as symptoms, treatment regimen, dietary supplements, and impact on lifestyle was obtained using a standard questionnaire. Patients were continuously monitored by health care providers and their oxygen saturation levels were also measured.


Results: According to results, 76% were suffering from fever as an initial symptom, followed by cough (52%), muscle weakness (93%), and dizziness (88%) and 5% of patients were asymptomatic. Commonly used medications were analgesics and antipyretics, antiplatelet drugs, bronchodilators, and vitamins. The important food utilized by corona patients was vegetables, fresh fruits and juices, animal-source foods, unsalted nuts, legumes, and whole grains. The treatment duration varies depending upon the condition and immunity of the patients with an average recovery period of 16.7±5.4 days.


Conclusion: The results proved that management of non-severe COVID-19 patients at home with close monitoring is an encouraging step for improving the health condition of the patients, lowering the number of admitted patients in hospitals and the fatality rate.

Abstract 263 | pdf Downloads 57

References

[1] Jin, Y., Yang, H., Ji, W., Wu, W., Chen, S., Zhang, W., & Duan, G, 2020. Virology, epidemiology, pathogenesis, and control of COVID-19. Viruses. 12(4): 372. https://doi.org/10.3390/v12040372
[2] Zhang, J.J., Dong, X., Cao, Y.Y., Yuan, Y.D., Yang, Y.B., Yan, Y.Q., Akdis, C.A. and Gao, Y.D., 2020. Clinical characteristics of 140 patients infected with SARS‐CoV‐2 in Wuhan, China. Allergy. 75(7): 1730-1741. https://doi.org/10.1111/all.14238.
[3] Rothan, H.A. and Byrareddy, S.N., 2020. The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak.. J. Autoimmun. 109: 102433. https://doi.org/10.1016/j.jaut.2020.102433
[4] Qi, J., Zhou, Y., Hua, J., Zhang, L., Bian, J., Liu, B., Zhao, Z. and Jin, S., 2021. The scRNA- seq expression profiling of the receptor ACE2 and the cellular protease TMPRSS2 reveals human organs susceptible to SARS-CoV-2 infection. Int. J. Environ. Res. Public. Health. 18(1): 284. https://doi.org/10.3390/ijerph18010284
[5] Martines, R.B., Ritter, J.M., Matkovic, E., Gary, J., Bollweg, B.C., Bullock, H., Goldsmith, C.S., Silva-Flannery, L., Seixas, J.N., Reagan-Steiner, S. and Uyeki, T., 2020. Pathology and pathogenesis of SARS-CoV-2 associated with fatal coronavirus disease, United States. Emerg. Infect. Dis. 26(9): 2005. https://doi.org/10.3201%2Feid2609.202095
[6] Alishan, S., Ali, F., Iqbal, Z., Ammar, A., Muhammad, A.S., Farooq, F., Mir, A., Salahuddin, N., Saghir, T. and Karim, M., 2022. Home Management of COVID-19 Patients: A Successful Model in Non-severe COVID-19 Patients in the Developing World. Cureus. 14(1). doi: 10.7759/cureus.21605
[7] Sial N, Ahmad M, Hussain MS, Iqbal MJ, Hameed Y, Khan M, Abbas M, Asif R, Rehman JU, Atif M, Khan MR, Hameed Z, Saeed H, Tanveer R, Saeed S, Sharif A, Asif HM. CTHRC1 expression is a novel shared diagnostic and prognostic biomarker of survival in six different human cancer subtypes. Sci Rep. 2021 6;11(1):19873. doi: 10.1038/s41598-021-99321-w.
[8] Sial N, Saeed S, Ahmad M, Hameed Y, Rehman A, Abbas M, Asif R, Ahmed H, Hussain MS, Rehman JU, Atif M, Khan MR. Multi-Omics Analysis Identified TMED2 as a Shared Potential Biomarker in Six Subtypes of Human Cancer. Int J Gen Med. 2021 21;14:7025-7042. doi: 10.2147/IJGM.S327367.
[9] Usman M, Hameed Y, Ahmad M, Iqbal MJ, Maryam A, Mazhar A, Naz S, Tanveer R, Saeed H, Bint-E-Fatima, Ashraf A, Hadi A, Hameed Z, Tariq E, Aslam AS. SHMT2 is Associated with Tumor Purity, CD8+ T Immune Cells Infiltration, and a Novel Therapeutic Target in Four Different Human Cancers. Curr Mol Med. 2023;23(2):161-176. doi: 10.2174/1566524022666220112142409.
[10] Usman M, Hameed Y, Ahmad M. Does human papillomavirus cause human colorectal cancer? Applying Bradford Hill criteria postulates. Ecancermedicalscience. 2020 Sep 21;14:1107. doi: 10.3332/ecancer.2020.1107
[11] Brugliera, L., Spina, A., Castellazzi, P., Cimino, P., Arcuri, P., Negro, A., Houdayer, E., Alemanno, F., Giordani, A., Mortini, P. and Iannaccone, S., 2020. Nutritional management of COVID-19 patients in a rehabilitation unit. Eur. J. Clin. Nutr. 74(6): 860-863. https://doi.org/10.1038/s41430-020-0664-x
[12] Reese, J.T., Coleman, B., Chan, L., Blau, H., Callahan, T.J., Cappelletti, L., Fontana, T., Bradwell, K.R., Harris, N.L., Casiraghi, E. and Valentini, G., 2022. NSAID use and clinical outcomes in COVID-19 patients: a 38-center retrospective cohort study. Virol. J. 19(1): 84. https://doi.org/10.1186/s12985-022-01813-2
[13] Perico, N., Cortinovis, M., Suter, F. and Remuzzi, G., 2023. Home as the new frontier for the treatment of COVID-19: the case for anti-inflammatory agents. Lancet Infect. Dis. 23(1): e22-e33. https://doi.org/10.1016/S1473-3099(22)00433-9
[14] Tang, N., Bai, H., Chen, X., Gong, J., Li, D. and Sun, Z., 2020. Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. J Thromb. Haemost. 18(5): 1094-1099. https://doi.org/10.1111/jth.14817
[15] Hameed Y, Ejaz S. TP53 lacks tetramerization and N-terminal domains due to novel inactivating mutations detected in leukemia patients. J Cancer Res Ther. 2021 Jul-Sep;17(4):931-937. doi: 10.4103/jcrt.JCRT_536_19.
[16] Boyle, A.J., Di Gangi, S., Hamid, U.I., Mottram, L.J., McNamee, L., White, G., Cross, L.J., McNamee, J.J., O’Kane, C.M. and McAuley, D.F., 2015. Aspirin therapy in patients with acute respiratory distress syndrome (ARDS) is associated with reduced intensive care unit mortality: a prospective analysis. Crit. Care. 19(1): 1-8. https://doi.org/10.1186/s13054-015-0846-4
[17] Aydin, S. and Aydin, S., 2020. Could Antihistamines Help in the Treatment and Spread of COVID-19 Via Re-Modulating Cytokines and by Reducing Sneezing?. Act. Sci. Nutr. Health. 4(4): 172-173.
[18] Blanco, J.I.M., Bonilla, J.A.A., Fremont-Smith, P. and de Las Heras, K.V.G., 2023. Antihistamines as an early treatment for Covid-19. Heliyon. 9(5). https://doi.org/10.1016/j.heliyon.2023.e15772
[19] Brennan, C.M., Nadella, S., Zhao, X., Dima, R.J., Jordan-Martin, N., Demestichas, B.R., Kleeman, S.O., Ferrer, M., von Gablenz, E.C., Mourikis, N. and Rubin, M.E., 2022. Oral famotidine versus placebo in non-hospitalised patients with COVID-19: a randomised, double- blind, data-intense, phase 2 clinical trial. Gut. 71(5): 879-888. http://dx.doi.org/10.1136/gutjnl- 2022-326952
[20] Cheema, H.A., Shafiee, A., Athar, M.M.T., Shahid, A., Awan, R.U., Afifi, A.M., Shah, J. and Jalal, P.K., 2023. No evidence of clinical efficacy of famotidine for the treatment of COVID- 19: a systematic review and meta-analysis. . J. Infect. 86(2): 154-225. https://doi.org/10.1016/j.jinf.2022.11.022
[21] Chen, I.S. and Kubo, Y., 2018. Ivermectin and its target molecules: shared and unique modulation mechanisms of ion channels and receptors by ivermectin. J. Physiol. 596(10): 1833- 1845. https://doi.org/10.1113/JP275236
[22] Caly, L., Druce, J.D., Catton, M.G., Jans, D.A. and Wagstaff, K.M., 2020. The FDA- approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro. Antiviral. Res. 178: 104787. https://doi.org/10.1016/j.antiviral.2020.104787
[23] Kerr, L., Baldi, F., Lobo, R., Assagra, W.L., Proença, F.C., Chamie, J.J., Hibberd, J.A., Kory, P., Cadegiani, F.A., Assagra Sr, W.L. and Proença Sr, F.C., 2022. Regular Use of Ivermectin as Prophylaxis for COVID-19 Led Up to a 92% Reduction in COVID-19 Mortality Rate in a Dose-Response Manner: Results of a Prospective Observational Study of a Strictly Controlled Population of 88,012 Subjects. Cureus. 14(8). DOI: 10.7759/cureus.28624
[24] Pan, L., Mu, M.I., Yang, P., Sun, Y., Wang, R., Yan, J., Li, P., Hu, B., Wang, J., Hu, C. and Jin, Y., 2020. Clinical characteristics of COVID-19 patients with digestive symptoms in Hubei, China: a descriptive, cross-sectional, multicenter study. Am. J. Gastroenterol. 115(5): 766-773. https://doi.org/10.14309%2Fajg.0000000000000620
[25] Meltzer, D.O., Best, T.J., Zhang, H., Vokes, T., Arora, V. and Solway, J., 2020. Association of vitamin D status and other clinical characteristics with COVID-19 test results. JAMA Netw. open. 3(9): e2019722-e2019722. doi:10.1001/jamanetworkopen.2020.19722
[26] Calder, P.C., Carr, A.C., Gombart, A.F. and Eggersdorfer, M., 2020. Optimal nutritional status for a well-functioning immune system is an important factor to protect against viral infections. Nutrients. 12(4): 1181. https://doi.org/10.3390/nu12041181
[27] Zhang, L. and Liu, Y., 2020. Potential interventions for novel coronavirus in China: A systematic review. J. Med. Virol. 92(5): 479-490. https://doi.org/10.1002/jmv.25707
[28] Alexander, J., Tinkov, A., Strand, T.A., Alehagen, U., Skalny, A. and Aaseth, J., 2020. Early nutritional interventions with zinc, selenium and vitamin D for raising anti-viral resistance against progressive COVID-19. Nutrients. 12(8): 2358. https://doi.org/10.3390/nu12082358
[29] Moghaddam, A., Heller, R.A., Sun, Q., Seelig, J., Cherkezov, A., Seibert, L., Hackler, J., Seemann, P., Diegmann, J., Pilz, M. and Bachmann, M., 2020. Selenium deficiency is associated with mortality risk from COVID-19. Nutrients. 12(7): 2098. https://doi.org/10.3390/nu12072098
[30] Sultana, J., Cutroneo, P.M., Crisafulli, S., Puglisi, G., Caramori, G. and Trifirò, G., 2020. Azithromycin in COVID-19 patients: pharmacological mechanism, clinical evidence and prescribing guidelines. Drug Saf. 43: 691-698. https://doi.org/10.1007/s40264-020-00976-7
[31] Aït Moussa, L., Tebaa, A., Alj, L., Sefiani, H., Meski, F.Z., Khattabi, A. and Soulaymani Bencheikh, R., 2023. Adverse drug reactions to chloroquine/hydroxychloroquine in combination with azithromycin in COVID-19 in-patients: data from intensive pharmacovigilance in Morocco, 2020. Naunyn-Schmiedebergs Arch. Pharmacol. 1-10. https://doi.org/10.1007/s00210-023- 02574-
[32] Iddir, M., Brito, A., Dingeo, G., Fernandez Del Campo, S.S., Samouda, H., La Frano, M.R. and Bohn, T., 2020. Strengthening the immune system and reducing inflammation and oxidative stress through diet and nutrition: considerations during the COVID-19 crisis. Nutrients. 12(6): 1562. https://doi.org/10.3390/nu12061562
[33] Zabetakis, I., Lordan, R., Norton, C. and Tsoupras, A., 2020. COVID-19: the inflammation link and the role of nutrition in potential mitigation. Nutrients. 12(5): 1466. https://doi.org/10.3390/nu12051466
[34] Fernández-Quintela, A., Milton-Laskibar, I., Trepiana, J., Gómez-Zorita, S., Kajarabille, N., Léniz, A., González, M. and Portillo, M.P., 2020. Key aspects in nutritional management of COVID-19 patients. J. Clin. Med. 9(8): 2589. https://doi.org/10.3390/jcm9082589
[35] Shivakoti, R., Biggs, M.L., Djoussé, L., Durda, P.J., Kizer, J.R., Psaty, B., Reiner, A.P., Tracy, R.P., Siscovick, D. and Mukamal, K.J., 2022. Intake and sources of dietary fiber, inflammation, and cardiovascular disease in older US adults. JAMA Netw. Open. 5(3): e225012- e225012

Most read articles by the same author(s)